Research Progress on the Treatment of Adenomyosis-Related Pain with Dienogest

doi:10.12280/gjfckx.20250166

Abstract

Abstract:

Dysmenorrhea is one of the main symptoms of adenomyosis (AM). The pathogenesis of AM-related pain involves multiple mechanisms. Dienogest, as one of the key drugs for the treatment of AM-related pain, plays an important role in the long-term management of AM. Basic research shows that dienogest can achieve the goals of reducing inflammation, decreasing pain hypersensitivity, and controlling the progression of AM through multiple mechanisms of action, such as inhibiting the proliferation and inflammatory response of ectopic endometrial stromal cells, promoting apoptosis, regulating the expression of nerve growth factors and the immune microenvironment, and inhibiting angiogenesis. Clinical research evidence further clarifies that dienogest is more effective than other drugs in relieving AM-related pain, improving uterine bleeding, and controlling uterine volume. It can be used as a long-term treatment drug for AM-related pain, providing a scientific basis for further in-depth research on the mechanism of action and clinical application of dienogest.

Key words: Adenomyosis, Pain, Therapy, Pain management, Dienogest

YAN Ying, YANG Yang, ZHONG Hua, LIANG Yan-chun. Research Progress on the Treatment of Adenomyosis-Related Pain with Dienogest[J]. Journal of International Obstetrics and Gynecology, 2025, 52(3): 246-251.

References 41

[1]	Dason ES, Maxim M, Sanders A, et al. Guideline No.437: Diagnosis and Management of Adenomyosis[J]. J Obstet Gynaecol Can, 2023, 45(6):417-429.e1 doi: 10.1016/j.jogc.2023.04.008.
[2]	Alcock MM. Defining pain: past, present, and future[J]. Pain, 2017, 158(4):761-762. doi: 10.1097/j.pain.0000000000000828. pmid: 28301403
[3]	Chen Q, Li YW, Wang S, et al. Clinical Manifestations Of Adenomyosis Patients With Or Without Pain Symptoms[J]. J Pain Res, 2019, 12:3127-3133. doi: 10.2147/JPR.S212117. pmid: 31814754
[4]	Volcheck MM, Graham SM, Fleming KC, et al. Central sensitization, chronic pain, and other symptoms: Better understanding, better management[J]. Cleve Clin J Med, 2023, 90(4):245-254. doi: 10.3949/ccjm.90a.22019.
[5]	Bourdon M, Santulli P, Jeljeli M, et al. Immunological changes associated with adenomyosis: a systematic review[J]. Hum Reprod Update, 2021, 27(1):108-129. doi: 10.1093/humupd/dmaa038. pmid: 33099635
[6]	Zhai J, Vannuccini S, Petraglia F, et al. Adenomyosis: Mechanisms and Pathogenesis[J]. Semin Reprod Med, 2020, 38(2-03):129-143. doi: 10.1055/s-0040-1716687. pmid: 33032339
[7]	Shi J, Xu Q, Yu S, et al. Perturbations of the endometrial immune microenvironment in endometriosis and adenomyosis: their impact on reproduction and pregnancy[J]. Semin Immunopathol, 2025, 47(1):16. doi: 10.1007/s00281-025-01040-1. pmid: 39966111
[8]	Cao Y, Yang D, Cai S, et al. Adenomyosis-associated infertility: an update of the immunological perspective[J]. Reprod Biomed Online, 2025, 50(5):104703. doi: 10.1016/j.rbmo.2024.104703.
[9]	Liu F, Liu L, Zheng J. Expression of annexin A2 in adenomyosis and dysmenorrhea[J]. Arch Gynecol Obstet, 2019, 300(3):711-716. doi: 10.1007/s00404-019-05205-w. pmid: 31183557
[10]	王舒, 甘卫冬, 金锦祥, 等. Slit-Robo细胞信号转导通路研究进展[J]. 生物化学与生物物理进展, 2022, 49(2):318-327. doi: 10.16476/j.pibb.2020.0329.
[11]	Nie J, Liu X, Zheng Y, et al. Increased immunoreactivity to SLIT/ROBO1 and its correlation with severity of dysmenorrhea in adenomyosis[J]. Fertil Steril, 2011, 95(3):1164-1167. doi: 10.1016/j.fertnstert.2010.09.027. pmid: 20970134
[12]	Chen Y, Zhu J, Chen L, et al. SFRP4+IGFBP5hi NKT cells induced neural-like cell differentiation to contribute to adenomyosis pain[J]. Front Immunol, 2022,13:945504. doi: 10.3389/fimmu.2022.945504.
[13]	Habiba M, Benagiano G, Guo SW. An Appraisal of the Tissue Injury and Repair (TIAR) Theory on the Pathogenesis of Endometriosis and Adenomyosis[J]. Biomolecules, 2023, 13(6):975. doi: 10.3390/biom13060975.
[14]	van Loo G, Bertrand M. Death by TNF: a road to inflammation[J]. Nat Rev Immunol, 2023, 23(5):289-303. doi: 10.1038/s41577-022-00792-3.
[15]	林燕丹, 潘琦文, 李建湘. 地诺孕素治疗子宫腺肌症痛经患者的临床效果及其作用机制研究[J]. 中国医药科学, 2024, 14(2):96-98,102. doi: 10.20116/j.issn2095-0616.2024.02.23.
[16]	Carrarelli P, Yen CF, Funghi L, et al. Expression of Inflammatory and Neurogenic Mediators in Adenomyosis[J]. Reprod Sci, 2017, 24(3):369-375. doi: 10.1177/1933719116657192. pmid: 27440813
[17]	Vannuccini S, Tosti C, Carmona F, et al. Pathogenesis of adenomyosis: an update on molecular mechanisms[J]. Reprod Biomed Online, 2017, 35(5):592-601. doi: 10.1016/j.rbmo.2017.06.016. pmid: 28693952
[18]	李雁, 张绍芬, 许琳娜. 子宫腺肌病病灶神经生长因子蛋白表达变化与神经植入及盆腔疼痛的关系[J]. 中华妇产科杂志, 2014, 49(2):120-124. doi: 10.3760/cma.j.issn.0529-567x.2014.02.009.
[19]	Li Y, Zhang D, Jin B, et al. Proteomic Analysis of Uterine Tissues During Peri-Implantation Period in Mice with Experimentally Induced Adenomyosis that Treated with anti-Ngf: Implications for Cell-Cell Adhesion and Metabolic Processes[J]. Reprod Sci, 2021, 28(1):207-217. doi: 10.1007/s43032-020-00262-y.
[20]	Yalaza C, Canacankatan N, Gürses, et al. Altered VEGF, Bcl-2 and IDH1 expression in patients with adenomyosis[J]. Arch Gynecol Obstet, 2020, 302(5):1221-1227. doi: 10.1007/s00404-020-05742-9. pmid: 32785780
[21]	Orazov MR, Nosenko EN, Radzinsky VE, et al. Proangiogenic features in chronic pelvic pain caused by adenomyosis[J]. Gynecol Endocrinol, 2016, 32(Suppl 2):7-10. doi: 10.1080/09513590.2016.1232902.
[22]	Stratopoulou CA, Donnez J, Dolmans MM. Origin and Pathogenic Mechanisms of Uterine Adenomyosis: What Is Known So Far[J]. Reprod Sci, 2021, 28(8):2087-2097. doi: 10.1007/s43032-020-00361-w. pmid: 33090375
[23]	Wang S, Duan H, Zhang Y, et al. Abnormal Activation of RhoA/ROCK-I Signaling in Junctional Zone Smooth Muscle Cells of Patients With Adenomyosis[J]. Reprod Sci, 2016, 23(3):333-341. doi: 10.1177/1933719115602764. pmid: 26335177
[24]	Jiang C, Gong W, Chen R, et al. RhoA/ROCK/ARHGAP26 signaling in the eutopic and ectopic endometrium is involved in clinical characteristics of adenomyosis[J]. J Int Med Res, 2018, 46(12):5019-5029. doi: 10.1177/0300060518789038. pmid: 30387365
[25]	Osuga Y, Fujimoto-Okabe H, Hagino A. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study[J]. Fertil Steril, 2017, 108(4):673-678. doi: 10.1016/j.fertnstert.2017.07.021. pmid: 28911934
[26]	Vannuccini S, Luisi S, Tosti C, et al. Role of medical therapy in the management of uterine adenomyosis[J]. Fertil Steril, 2018, 109(3):398-405. doi: 10.1016/j.fertnstert.2018.01.013. pmid: 29566852
[27]	Kobayashi H. Efficacy, Adverse Events, and Challenges of Dienogest in the Management of Symptomatic Adenomyosis: A Comparison with Different Hormonal Treatments[J]. Gynecol Obstet Invest, 2023, 88(2):71-80. doi: 10.1159/000529185.
[28]	Ali MK, Hussein RS, Abdallah KS, et al. The use of dienogest in treatment of symptomatic adenomyosis: A systematic review and meta-analysis[J]. J Gynecol Obstet Hum Reprod, 2024, 53(7):102795. doi: 10.1016/j.jogoh.2024.102795.
[29]	Yamanaka A, Kimura F, Kishi Y, et al. Progesterone and synthetic progestin, dienogest, induce apoptosis of human primary cultures of adenomyotic stromal cells[J]. Eur J Obstet Gynecol Reprod Biol, 2014, 179:170-174. doi: 10.1016/j.ejogrb.2014.05.031. pmid: 24953822
[30]	Takeuchi A, Koga K, Miyashita M, et al. Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis[J]. Eur J Obstet Gynecol Reprod Biol, 2016, 207:157-161. doi: 10.1016/j.ejogrb.2016.10.053. pmid: 27865118
[31]	Prathoomthong S, Tingthanatikul Y, Lertvikool S, et al. The Effects of Dienogest on Macrophage and Natural Killer Cells in Adenomyosis: A Randomized Controlled Study[J]. Int J Fertil Steril, 2018, 11(4):279-286. doi: 10.22074/ijfs.2018.5137. pmid: 29043703
[32]	Ota I, Taniguchi F, Ota Y, et al. A controlled clinical trial comparing potent progestins, LNG-IUS and dienogest, for the treatment of women with adenomyosis[J]. Reprod Med Biol, 2021, 20(4):427-434. doi: 10.1002/rmb2.12408. pmid: 34646070
[33]	Guo W, Lin Y, Hu S, et al. Compare the Efficacy of Dienogest and the Levonorgestrel Intrauterine System in Women with Adenomyosis[J]. Clin Ther, 2023, 45(10):973-976. doi: 10.1016/j.clinthera.2023.07.019.
[34]	Choudhury S, Jena SK, Mitra S, et al. Comparison of efficacy between levonorgestrel intrauterine system and dienogest in adenomyosis: a randomized clinical trial[J]. Ther Adv Reprod Health, 2024,18:26334941241227401. doi: 10.1177/26334941241227401.
[35]	Hassanin AI, Youssef AA, Yousef AM, et al. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial[J]. Int J Gynaecol Obstet, 2021, 154(2):263-269. doi: 10.1002/ijgo.13600. pmid: 33454995
[36]	Chan IS, Hsu TF, Shih YC, et al. Maintenance dienogest therapy following adjuvant gonadotropin-releasing hormone agonist treatment after uterus-sparing surgery in adenomyosis: A retrospective cohort study[J]. Int J Gynaecol Obstet, 2023, 161(3):751-759. doi: 10.1002/ijgo.14635.
[37]	Ota K, Takahashi T, Shiraishi S, et al. Combination of microwave endometrial ablation and postoperative dienogest administration is effective for treating symptomatic adenomyosis[J]. J Obstet Gynaecol Res, 2018, 44(9):1787-1792. doi: 10.1111/jog.13720.
[38]	Neriishi K, Hirata T, Fukuda S, et al. Long-term dienogest administra- tion in patients with symptomatic adenomyosis[J]. J Obstet Gynaecol Res, 2018, 44(8):1439-1444. doi: 10.1111/jog.13674.
[39]	Chen CH, Lin YH, Lee CY, et al. Long-term clinical outcomes of dienogest for perimenopausal women with symptomatic adenomyosis[J]. Sci Rep, 2025, 15(1):8174. doi: 10.1038/s41598-025-93156-5.
[40]	Miao J, Lu J, Tang J, et al. Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice[J]. Gynecol Endocrinol, 2022, 38(8):656-660. doi: 10.1080/09513590.2022.2098948.
[41]	Lin S, Chen Y, Yi J, et al. Dienogest treatment of symptomatic adenomyosis: An in-depth meta-analysis[J]. Eur J Obstet Gynecol Reprod Biol, 2025, 305:365-374. doi: 10.1016/j.ejogrb.2024.12.048. pmid: 39754909